Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit



Thursday, Baxter International Inc (NYSE: BAX) posted a fourth-quarter 2023 revenue of $3.89 billion, which beat the consensus of $3.80 billion, up 4% Y/Y on a reported basis and 3% on a constant currency.

Baxter guided fourth-quarter sales growth of 1%-2% on a reported basis and approximately 1% on a constant currency basis.

Fourth-quarter sales performance exceeded guidance, driven by better-than-expected sales in the company’s Medical Products and Therapies, Kidney Care, and Pharmaceuticals segments

Sales growth in the quarter was driven by strong performance in the Healthcare …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *